Redeye, in this research update, goes into more detail on its new and higher fair value range for Mycronic. Simply put, the new detailed reporting of the four divisions has given some important leads regarding current as well as future growth and margins etc. The Q4 was indeed weak, but we argue that this is just a temporary setback in Mycronic’s chronic growth story. We also comment on some rumors around eventual new competition in PG.